Notable Analyst Upgrades and Downgrades for Week of May 23 2022

 

Upgrades:

 

Consolidated Edison (NYSE:ED) was upgraded by research analysts at Guggenheim from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage currently has a $94.00 price target on the utilities provider’s stock. Guggenheim’s target price would suggest a potential downside of 6.37% from the stock’s previous close.

Several other equities research analysts also recently commented on ED. The Goldman Sachs Group boosted their target price on shares of Consolidated Edison from $65.00 to $83.00 and gave the company a “sell” rating in a research note on Thursday, March 31st. Royal Bank of Canada upped their price target on shares of Consolidated Edison from $88.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Monday, March 28th. Wells Fargo & Company downgraded shares of Consolidated Edison from an “equal weight” rating to a “sell” rating and upped their price target for the stock from $85.00 to $94.00 in a research report on Tuesday, May 3rd. KeyCorp upped their price target on shares of Consolidated Edison from $71.00 to $72.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 20th. Finally, Credit Suisse Group began coverage on shares of Consolidated Edison in a research report on Monday, April 25th. They set a “neutral” rating and a $100.00 price target on the stock. Six investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $84.58. Read more …

 

DTE Energy (NYSE:DTE) was upgraded by analysts at Credit Suisse Group from a “neutral” rating to an “outperform” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a $140.00 target price on the utilities provider’s stock, down from their previous target price of $142.00. Credit Suisse Group’s target price points to a potential upside of 4.37% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Argus lifted their price objective on shares of DTE Energy from $130.00 to $132.00 in a report on Thursday, March 10th. Bank of America upgraded shares of DTE Energy from an “underperform” rating to a “buy” rating and set a $127.00 price target on the stock in a report on Tuesday, February 15th. Citigroup boosted their price target on shares of DTE Energy from $134.00 to $146.00 in a report on Tuesday, May 3rd. StockNews.com began coverage on shares of DTE Energy in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Morgan Stanley lifted their price objective on shares of DTE Energy from $133.00 to $143.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $130.91. Read more …

 

JPMorgan Chase & Co. (NYSE:JPM) was upgraded by Societe Generale from a “hold” rating to a “buy” rating in a report issued on Tuesday, Briefing.com reports.

A number of other research analysts also recently weighed in on JPM. Argus lowered their price objective on shares of JPMorgan Chase & Co. from $177.00 to $155.00 in a research report on Thursday, April 14th. The Goldman Sachs Group set a $151.00 price objective on shares of JPMorgan Chase & Co. and gave the company a “buy” rating in a research report on Thursday, April 14th. Zacks Investment Research upgraded shares of JPMorgan Chase & Co. from a “sell” rating to a “hold” rating and set a $147.00 price objective on the stock in a research report on Monday, March 21st. Royal Bank of Canada set a $175.00 price objective on shares of JPMorgan Chase & Co. and gave the company an “outperform” rating in a research report on Thursday, April 14th. Finally, Barclays set a $200.00 price target on shares of JPMorgan Chase & Co. in a research report on Monday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $161.67. Read more …

 

 

Air Products and Chemicals (NYSE:APD) was upgraded by investment analysts at Atlantic Securities from a "neutral" rating to an "overweight" rating in a report issued on Wednesday, The Fly reports. The brokerage presently has a $290.00 price target on the basic materials company's stock, up from their previous price target of $280.00. Atlantic Securities' target price would indicate a potential upside of 22.46% from the stock's current price.

APD has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Air Products and Chemicals from $300.00 to $272.00 in a research report on Tuesday, May 10th. BMO Capital Markets downgraded shares of Air Products and Chemicals from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $383.00 to $280.00 in a report on Tuesday, February 8th. Credit Suisse Group reduced their price target on shares of Air Products and Chemicals from $302.00 to $290.00 and set an "outperform" rating on the stock in a report on Friday, May 20th. JPMorgan Chase & Co. raised shares of Air Products and Chemicals from a "neutral" rating to an "overweight" rating and set a $275.00 price objective on the stock in a research note on Monday, March 21st. Finally, Wells Fargo & Company lowered shares of Air Products and Chemicals from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $275.00 to $255.00 in a research report on Wednesday, May 11th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, Air Products and Chemicals presently has a consensus rating of "Buy" and an average price target of $303.00. Read more …

Notable Analyst Upgrades and Downgrades for Week of May 16 2022

 

Upgrades:

 

Canadian Western Bank (TSE:CWB) was upgraded by research analysts at National Bank Financial from a “sector perform market weight” rating to an “outperform market weight” rating in a research report issued to clients and investors on Sunday.

A number of other brokerages have also weighed in on CWB. National Bankshares upgraded Canadian Western Bank from a “sector perform” rating to a “buy” rating and set a C$44.00 price objective on the stock in a research report on Monday. TD Securities boosted their price objective on Canadian Western Bank from C$43.00 to C$47.00 in a research report on Tuesday, February 15th. Raymond James boosted their price objective on Canadian Western Bank from C$41.00 to C$43.00 and gave the stock an “outperform” rating in a research report on Monday, February 28th. CIBC lowered Canadian Western Bank from an “outperform” rating to a “hold” rating and reduced their price objective for the stock from C$45.00 to C$38.00 in a research report on Monday, April 11th. Finally, Barclays reduced their price objective on Canadian Western Bank from C$44.00 to C$38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 11th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of C$42.86. Read more …

 

Essex Property Trust (NYSE:ESS) was upgraded by analysts at The Goldman Sachs Group from a "sell" rating to a "buy" rating in a report issued on Tuesday, The Fly reports. The firm presently has a $338.00 target price on the real estate investment trust's stock, down from their previous target price of $352.00. The Goldman Sachs Group's price objective would indicate a potential upside of 15.80% from the company's current price.

Several other research analysts have also recently issued reports on ESS. TheStreet cut shares of Essex Property Trust from a "b-" rating to a "c+" rating in a report on Friday. Truist Financial cut their target price on shares of Essex Property Trust from $378.00 to $370.00 and set a "buy" rating for the company in a research note on Monday, March 21st. Piper Sandler cut their target price on shares of Essex Property Trust from $420.00 to $400.00 in a research note on Wednesday, May 4th. Morgan Stanley increased their target price on shares of Essex Property Trust from $335.00 to $365.00 and gave the company an "equal weight" rating in a research note on Friday, April 8th. Finally, StockNews.com started coverage on shares of Essex Property Trust in a research note on Thursday, March 31st. They set a "hold" rating for the company. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $359.00. Read more …

 

Cardinal Health (NYSE:CAH) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating in a report issued on Wednesday, Briefing.com reports. The brokerage presently has a $68.00 price target on the stock, up from their prior price target of $55.00. Evercore ISI's target price would suggest a potential upside of 19.93% from the company's current price.

Several other analysts also recently commented on the stock. Credit Suisse Group dropped their target price on shares of Cardinal Health from $60.00 to $58.00 and set a "neutral" rating on the stock in a report on Friday, February 4th. StockNews.com cut shares of Cardinal Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 6th. TheStreet cut shares of Cardinal Health from a "c+" rating to a "d+" rating in a research note on Thursday, May 5th. Zacks Investment Research raised shares of Cardinal Health from a "sell" rating to a "hold" rating and set a $55.00 price target for the company in a research note on Monday, March 14th. Finally, Morgan Stanley raised shares of Cardinal Health from an "equal weight" rating to an "overweight" rating and set a $74.00 price target for the company in a research note on Tuesday, April 12th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Cardinal Health has a consensus rating of "Hold" and an average target price of $59.90. Read more …

 

 

Canadian National Railway (NYSE:CNI) (TSE:CNR) was upgraded by research analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating in a research note issued to investors on Wednesday, The Fly reports.

A number of other brokerages also recently commented on CNI. StockNews.com assumed coverage on Canadian National Railway in a research report on Thursday, March 31st. They issued a "hold" rating for the company. Argus raised Canadian National Railway from a "hold" rating to a "buy" rating and set a $145.00 price target for the company in a research report on Thursday, February 17th. They noted that the move was a valuation call. Desjardins reduced their price objective on Canadian National Railway from C$173.00 to C$172.00 in a research note on Thursday, April 28th. Scotiabank cut their price target on Canadian National Railway from C$174.00 to C$172.00 in a research note on Wednesday, April 27th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Canadian National Railway from $137.00 to $142.00 and gave the company a "buy" rating in a report on Thursday, January 27th. Seventeen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Canadian National Railway currently has an average rating of "Hold" and a consensus target price of $147.76. Read more …

Dividend Increases Week 19

 

In this article, I will go through the weekly dividend increases and cuts in popular and well-known stocks. (Member of The Dividend Champions or Canadian All-Star list)

 

Recently, 11 companies announced dividend increases. Note that no dividend cuts or suspensions were announced during this period.

Notable Analyst Upgrades and Downgrades for Week of April 11 2022 (Part 1)

 

Upgrades:

 

Domino’s Pizza (NYSE:DPZ) was upgraded by Citigroup from a “neutral” rating to a “buy” rating in a note issued to investors on Monday, The Fly reports.

Other equities analysts also recently issued reports about the stock. Stephens raised shares of Domino’s Pizza from an “underweight” rating to an “equal weight” rating and cut their price target for the company from $500.00 to $425.00 in a report on Wednesday, March 2nd. Oppenheimer reduced their price objective on shares of Domino’s Pizza from $550.00 to $510.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 2nd. Morgan Stanley cut their price target on shares of Domino’s Pizza from $535.00 to $460.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 2nd. Royal Bank of Canada cut their price objective on shares of Domino’s Pizza from $550.00 to $525.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 2nd. Finally, Loop Capital downgraded shares of Domino’s Pizza from a “buy” rating to a “hold” rating and set a $413.00 target price on the stock. in a report on Wednesday, March 9th. One equities research analyst has rated the stock with a sell rating, twenty have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $480.73. Read more …

 

KeyCorp (NYSE:KEY) was upgraded by research analysts at Wells Fargo & Company from an “underweight” rating to an “overweight” rating in a research note issued to investors on Monday, The Fly reports. The firm currently has a $27.00 price target on the financial services provider’s stock, up from their previous price target of $23.00. Wells Fargo & Company‘s price objective suggests a potential upside of 30.00% from the company’s current price.

KEY has been the subject of several other reports. Barclays upped their target price on KeyCorp from $24.00 to $26.00 in a research note on Monday, January 3rd. Bank of America upgraded KeyCorp from an “underperform” rating to a “buy” rating and upped their target price for the stock from $25.00 to $27.00 in a research note on Wednesday, December 15th. UBS Group initiated coverage on KeyCorp in a research note on Wednesday, January 12th. They set a “buy” rating and a $32.00 target price for the company. StockNews.com initiated coverage on KeyCorp in a research note on Thursday, March 31st. They set a “hold” rating for the company. Finally, Credit Suisse Group upgraded KeyCorp from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 8th. Six analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, KeyCorp has an average rating of “Buy” and a consensus price target of $27.21. Read more …

 

National Bank of Canada (TSE:NA) was upgraded by stock analysts at CIBC to a “buy” rating in a research report issued on Monday, TipRanks reports. The firm currently has a C$102.00 price objective on the financial services provider’s stock. CIBC’s price target would suggest a potential upside of 7.71% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group raised their price target on shares of National Bank of Canada from C$108.00 to C$109.00 in a research note on Thursday, February 17th. Cormark lifted their price objective on shares of National Bank of Canada from C$118.00 to C$123.00 and gave the company a “buy” rating in a research note on Monday, February 28th. BMO Capital Markets lifted their price objective on shares of National Bank of Canada from C$104.00 to C$108.00 in a report on Monday, February 28th. TD Securities boosted their price objective on shares of National Bank of Canada from C$105.00 to C$110.00 in a research report on Tuesday, February 15th. Finally, Scotiabank upped their target price on shares of National Bank of Canada from C$117.00 to C$119.00 in a research note on Monday, February 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of C$103.81. Read more …

 

 

Pembina Pipeline (NYSE:PBA) (TSE:PPL) was upgraded by equities research analysts at Credit Suisse Group from a “neutral” rating to an “outperform” rating in a research report issued on Monday, The Fly reports.

A number of other equities research analysts have also weighed in on PBA. TD Securities initiated coverage on shares of Pembina Pipeline in a report on Thursday, March 3rd. They set a “buy” rating for the company. Canaccord Genuity Group lifted their price target on shares of Pembina Pipeline from C$47.00 to C$49.00 in a report on Wednesday, March 2nd. Zacks Investment Research upgraded shares of Pembina Pipeline from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research report on Monday, March 14th. BMO Capital Markets upgraded shares of Pembina Pipeline from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 1st. Finally, Scotiabank boosted their price target on shares of Pembina Pipeline from C$47.00 to C$49.00 in a report on Wednesday, March 2nd. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $44.75. Read more …

 

Royal Bank of Canada (TSE:RY) (NYSE:RY) was upgraded by analysts at CIBC to a “buy” rating in a research note issued to investors on Monday, TipRanks reports. The brokerage currently has a C$149.00 price objective on the financial services provider’s stock. CIBC’s price target suggests a potential upside of 8.17% from the company’s previous close.

Several other analysts have also recently weighed in on RY. Fundamental Research reduced their price target on Royal Bank of Canada from C$152.07 to C$151.16 and set a “buy” rating on the stock in a report on Monday, March 7th. National Bankshares boosted their target price on Royal Bank of Canada from C$140.00 to C$147.00 in a research report on Wednesday, February 23rd. Barclays increased their price target on shares of Royal Bank of Canada from C$141.00 to C$157.00 and gave the company an “overweight” rating in a research report on Wednesday, January 19th. Canaccord Genuity Group boosted their price target on shares of Royal Bank of Canada from C$148.00 to C$150.00 in a research report on Thursday, February 17th. Finally, TD Securities boosted their target price on shares of Royal Bank of Canada from C$150.00 to C$165.00 in a research report on Tuesday, February 15th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of C$147.15. Read more …

 

Wells Fargo & Company (NYSE:WFC) was upgraded by research analysts at Citigroup from a “neutral” rating to a “buy” rating in a report issued on Monday, The Fly reports.

WFC has been the subject of several other reports. Barclays upgraded Wells Fargo & Company from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $50.00 to $62.00 in a research report on Monday, January 3rd. Piper Sandler lowered their price objective on Wells Fargo & Company from $67.00 to $63.00 and set an “overweight” rating for the company in a research report on Thursday, March 31st. Morgan Stanley lowered their price objective on Wells Fargo & Company from $72.00 to $66.00 and set an “overweight” rating for the company in a research report on Monday, March 28th. JPMorgan Chase & Co. increased their price objective on Wells Fargo & Company from $57.00 to $58.50 in a research report on Thursday, February 3rd. Finally, StockNews.com started coverage on Wells Fargo & Company in a research report on Thursday, March 31st. They set a “hold” rating for the company. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $57.58. Read more …

 

 

Cardinal Health (NYSE:CAH) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report released on Tuesday, Briefing.com reports. The brokerage currently has a $74.00 target price on the stock. Morgan Stanley’s price target would suggest a potential upside of 20.56% from the stock’s current price.

CAH has been the subject of several other research reports. Credit Suisse Group lowered their price objective on shares of Cardinal Health from $60.00 to $58.00 and set a “neutral” rating for the company in a research note on Friday, February 4th. Zacks Investment Research raised Cardinal Health from a “sell” rating to a “hold” rating and set a $55.00 price objective for the company in a research note on Monday, March 14th. Robert W. Baird increased their price objective on Cardinal Health from $52.00 to $57.00 in a research note on Friday, February 4th. StockNews.com cut Cardinal Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 24th. Finally, TheStreet cut Cardinal Health from a “b” rating to a “c” rating in a report on Thursday, February 3rd. Two analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $58.10. Read more …

 

 

Downgrades:

 

American Express (NYSE:AXP) was downgraded by JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report issued on Monday, The Fly reports.

A number of other equities research analysts also recently commented on AXP. Wells Fargo & Company lifted their target price on American Express from $200.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, January 26th. BMO Capital Markets lifted their target price on shares of American Express from $152.00 to $155.00 and gave the company a “market perform” rating in a research report on Wednesday, January 26th. Deutsche Bank Aktiengesellschaft raised their price target on shares of American Express from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, January 26th. Daiwa Capital Markets raised shares of American Express from a “neutral” rating to a “buy” rating and raised their price target for the stock from $190.00 to $215.00 in a research note on Thursday, February 10th. Finally, Stephens lifted their target price on shares of American Express from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 26th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $197.71. Read more …

 

 

Bank of Nova Scotia (TSE:BNS) (NYSE:BNS) was downgraded by equities research analysts at CIBC from an “outperform” rating to a “neutral” rating in a report released on Monday, BayStreet.CA reports. They presently have a C$94.00 target price on the bank’s stock, down from their prior target price of C$105.00. CIBC’s target price would indicate a potential upside of 7.24% from the company’s previous close.

BNS has been the subject of several other research reports. TD Securities downgraded shares of Bank of Nova Scotia from a “buy” rating to a “hold” rating and set a C$100.00 price objective for the company. in a report on Thursday, March 10th. National Bankshares raised their price target on Bank of Nova Scotia from C$86.00 to C$90.00 in a report on Wednesday, February 23rd. BMO Capital Markets lifted their target price on Bank of Nova Scotia from C$93.00 to C$95.00 in a report on Wednesday, March 2nd. Barclays boosted their price objective on Bank of Nova Scotia from C$84.00 to C$96.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 19th. Finally, Canaccord Genuity Group boosted their price objective on Bank of Nova Scotia from C$98.00 to C$100.00 in a research report on Thursday, February 17th. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of C$92.72. Read more …

 

Canadian Western Bank (TSE:CWB) was downgraded by analysts at CIBC to a “hold” rating in a report released on Monday, TipRanks reports. They currently have a C$38.00 price objective on the stock. CIBC’s price objective would indicate a potential upside of 10.47% from the stock’s previous close.

A number of other research analysts have also recently weighed in on CWB. National Bankshares lifted their price objective on shares of Canadian Western Bank from C$43.00 to C$44.00 and gave the company a “sector perform” rating in a report on Tuesday, March 1st. TD Securities upped their price target on shares of Canadian Western Bank from C$43.00 to C$47.00 in a research note on Tuesday, February 15th. BMO Capital Markets boosted their price objective on shares of Canadian Western Bank from C$42.00 to C$42.50 in a research report on Monday, February 28th. Finally, Raymond James upped their target price on shares of Canadian Western Bank from C$41.00 to C$43.00 and gave the company an “outperform” rating in a report on Monday, February 28th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of C$42.86. Read more …

 

Kinder Morgan (NYSE:KMI) was downgraded by Wolfe Research from a “peer perform” rating to an “underperform” rating in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. They presently have a $18.00 target price on the pipeline company’s stock, up from their prior target price of $17.00. Wolfe Research’s price target would suggest a potential downside of 7.60% from the company’s current price.

Several other research firms also recently weighed in on KMI. StockNews.com initiated coverage on Kinder Morgan in a research report on Thursday, March 31st. They set a “hold” rating for the company. Barclays lifted their price objective on Kinder Morgan from $18.00 to $19.00 in a report on Thursday, January 20th. Finally, Zacks Investment Research upgraded shares of Kinder Morgan from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Tuesday, January 25th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Kinder Morgan presently has an average rating of “Hold” and an average price target of $18.36. Read more …

 

 

Starbucks (NASDAQ:SBUX) was downgraded by equities researchers at Citigroup from a “buy” rating to a “neutral” rating in a report issued on Monday, The Fly reports.

SBUX has been the subject of several other reports. Wedbush cut Starbucks from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $105.00 to $91.00 in a report on Tuesday, April 5th. Barclays reduced their price target on Starbucks from $136.00 to $125.00 and set an “overweight” rating for the company in a research report on Wednesday, February 2nd. Zacks Investment Research raised Starbucks from a “sell” rating to a “hold” rating and set a $95.00 price objective for the company in a report on Monday, March 21st. Jefferies Financial Group cut their price objective on Starbucks from $142.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, February 2nd. Finally, Cowen lowered their price objective on Starbucks from $125.00 to $115.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 2nd. Fifteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $113.50. Read more …

 

Toronto-Dominion Bank (TSE:TD) (NYSE:TD) was downgraded by investment analysts at CIBC from an “outperform” rating to a “neutral” rating in a research note issued on Monday, BayStreet.CA reports. They currently have a C$103.00 target price on the stock, down from their prior target price of C$115.00. CIBC’s target price would suggest a potential upside of 5.81% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity Group dropped their price objective on shares of Toronto-Dominion Bank from C$110.50 to C$106.00 in a research note on Friday, March 4th. Barclays increased their price target on shares of Toronto-Dominion Bank from C$99.00 to C$111.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 19th. Scotiabank cut their price target on shares of Toronto-Dominion Bank from C$117.00 to C$116.00 in a research note on Friday, March 4th. Royal Bank of Canada raised their price objective on shares of Toronto-Dominion Bank from C$104.00 to C$113.00 and gave the stock a “sector perform” rating in a research report on Friday, March 4th. Finally, BMO Capital Markets lowered their target price on shares of Toronto-Dominion Bank from C$105.00 to C$100.00 in a report on Friday, March 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Toronto-Dominion Bank presently has an average rating of “Hold” and a consensus price target of C$102.35. Read more …

 

TC Energy (TSE:TRP) (NYSE:TRP) was downgraded by stock analysts at Wolfe Research to a “sell” rating in a report released on Monday, TipRanks reports. They currently have a C$57.00 target price on the stock. Wolfe Research’s target price would suggest a potential downside of 21.71% from the company’s current price.

A number of other research analysts have also recently commented on the company. The Goldman Sachs Group cut TC Energy from a “neutral” rating to a “sell” rating in a research report on Thursday, January 13th. Tudor Pickering & Holt boosted their price target on TC Energy from C$63.00 to C$65.00 and gave the stock a “hold” rating in a report on Wednesday, February 16th. Industrial Alliance Securities upgraded TC Energy to a “buy” rating and set a C$74.00 target price on the stock in a report on Monday, April 4th. US Capital Advisors lowered TC Energy from an “overweight” rating to a “hold” rating in a research note on Friday, March 11th. Finally, Tudor Pickering upped their target price on TC Energy to C$65.00 and gave the stock a “hold” rating in a research report on Wednesday, February 16th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of C$68.64. Read more …

 

 

U.S. Bancorp (NYSE:USB) was downgraded by stock analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, The Fly reports.

Other equities analysts have also recently issued reports about the stock. UBS Group cut shares of U.S. Bancorp from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $64.00 to $56.00 in a research report on Friday. Morgan Stanley decreased their price objective on shares of U.S. Bancorp from $70.00 to $66.00 and set an “equal weight” rating for the company in a research report on Monday, March 28th. Oppenheimer decreased their price objective on shares of U.S. Bancorp from $74.00 to $69.00 in a research report on Friday, January 21st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of U.S. Bancorp in a research report on Friday, December 17th. Finally, Jefferies Financial Group cut shares of U.S. Bancorp from a “buy” rating to a “hold” rating and decreased their price objective for the company from $66.00 to $64.00 in a research report on Monday, February 14th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $64.29. Read more …

 

Notable Analyst Upgrades and Downgrades for Week of August 2, 2021

 

Upgrades:

 

AllianceBernstein (NYSE:AB) was upgraded by investment analysts at Citigroup from a “neutral” rating to a “buy” rating in a research note issued on Monday, The Fly reports. The brokerage presently has a $54.50 target price on the asset manager’s stock, up from their prior target price of $44.00. Citigroup’s price objective points to a potential upside of 12.91% from the company’s current price.

Several other equities research analysts also recently issued reports on the stock. Sanford C. Bernstein downgraded shares of AllianceBernstein from a “buy” rating to a “neutral” rating in a research report on Friday, April 9th. Keefe, Bruyette & Woods restated a “market perform” rating and set a $42.00 target price on shares of AllianceBernstein in a report on Tuesday, April 13th. Zacks Investment Research cut shares of AllianceBernstein from a “buy” rating to a “hold” rating in a report on Tuesday, July 27th. Finally, Bank of America restated a “neutral” rating and set a $42.00 target price on shares of AllianceBernstein in a report on Thursday, April 15th. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. AllianceBernstein currently has an average rating of “Hold” and a consensus price target of $44.36. Read more …

 

Welltower (NYSE:WELL) was upgraded by equities research analysts at Berenberg Bank from a "hold" rating to a "buy" rating in a note issued to investors on Tuesday, The Fly reports. The brokerage currently has a $100.00 price objective on the real estate investment trust's stock. Berenberg Bank's target price indicates a potential upside of 15.92% from the stock's previous close.

Other equities analysts also recently issued research reports about the company. Wells Fargo & Company boosted their price target on Welltower from $78.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Friday, July 23rd. Mizuho began coverage on Welltower in a research report on Wednesday, July 14th. They set a "neutral" rating and a $68.00 price target on the stock. Morgan Stanley boosted their price target on Welltower from $79.00 to $86.00 and gave the stock an "overweight" rating in a research report on Monday, July 26th. Capital One Financial raised Welltower from an "equal weight" rating to an "overweight" rating in a research report on Friday, May 21st. Finally, Wolfe Research began coverage on Welltower in a research report on Monday, June 14th. They set an "outperform" rating and a $94.00 price target on the stock. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of "Buy" and a consensus price target of $79.67. Read more …

 

Simon Property Group (NYSE:SPG) was upgraded by equities researchers at Bank of America from a "neutral" rating to a "buy" rating in a note issued to investors on Wednesday, The Fly reports.

Several other brokerages have also recently weighed in on SPG. Truist Securities boosted their price objective on Simon Property Group from $102.00 to $130.00 and gave the stock a "hold" rating in a report on Wednesday, June 23rd. UBS Group assumed coverage on Simon Property Group in a report on Thursday, June 3rd. They set a "neutral" rating and a $135.00 price objective for the company. BMO Capital Markets reissued a "hold" rating on shares of Simon Property Group in a report on Thursday, May 20th. Truist upped their price target on Simon Property Group from $102.00 to $130.00 and gave the company a "hold" rating in a research note on Wednesday, June 23rd. Finally, Stifel Nicolaus raised Simon Property Group from a "hold" rating to a "buy" rating and upped their price target for the company from $125.00 to $132.00 in a research note on Monday, July 19th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company. Simon Property Group has an average rating of "Hold" and an average price target of $128.13. Read more …

 

 

Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at DNB Markets from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, The Fly reports.

NVO has been the topic of a number of other reports. Barclays reiterated an “overweight” rating on shares of Novo Nordisk A/S in a report on Monday, July 19th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday. Finally, Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $91.00 price target on the stock in a report on Tuesday, July 13th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $91.00. Read more …

Notable Analyst Upgrades and Downgrades for Week of May 10, 2021

 

Upgrades:

 

NIKE (NYSE:NKE) was upgraded by stock analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a report released on Tuesday, The Fly reports. The brokerage currently has a $192.00 target price on the footwear maker’s stock, up from their prior target price of $140.00. Jefferies Financial Group’s price objective indicates a potential upside of 40.76% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Barclays reissued a “buy” rating and set a $174.00 target price on shares of NIKE in a research report on Friday, March 19th. Cowen boosted their target price on shares of NIKE from $170.00 to $173.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 23rd. Pivotal Research upped their price target on shares of NIKE from $160.00 to $167.00 and gave the company a “buy” rating in a report on Tuesday, March 16th. KeyCorp upped their price target on shares of NIKE from $174.00 to $180.00 and gave the company an “overweight” rating in a report on Monday, January 25th. Finally, Zacks Investment Research cut shares of NIKE from a “buy” rating to a “hold” rating and set a $146.00 price target on the stock. in a report on Monday, March 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and thirty-one have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $161.31. Read more …

 

Vodafone Group (NASDAQ:VOD) was upgraded by equities research analysts at The Goldman Sachs Group from a "buy" rating to a "conviction-buy" rating in a research report issued on Tuesday, The Fly reports.

A number of other equities research analysts have also recently weighed in on the stock. Morgan Stanley started coverage on shares of Vodafone Group in a research note on Thursday, March 25th. They set an "overweight" rating on the stock. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Vodafone Group in a research note on Friday. Barclays restated an "overweight" rating on shares of Vodafone Group in a research note on Thursday, February 4th. Zacks Investment Research cut shares of Vodafone Group from a "buy" rating to a "hold" rating in a research report on Tuesday, February 9th. Finally, JPMorgan Chase & Co. reiterated an "overweight" rating on shares of Vodafone Group in a research report on Thursday, February 4th. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. The company currently has a consensus rating of "Buy" and an average target price of $18.00.

Shares of NASDAQ VOD opened at $20.19 on Tuesday. Vodafone Group has a fifty-two week low of $13.14 and a fifty-two week high of $20.36. The firm's 50-day simple moving average is $18.91 and its 200 day simple moving average is $17.53. The company has a quick ratio of 1.10, a current ratio of 1.12 and a debt-to-equity ratio of 1.03. The stock has a market cap of $56.98 billion, a P/E ratio of 32.56, a P/E/G ratio of 1.16 and a beta of 0.97. Read more …

 

Eastman Chemical (NYSE:EMN) was upgraded by stock analysts at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research note issued on Tuesday, The Fly reports. The firm currently has a $148.00 target price on the basic materials company’s stock. The Goldman Sachs Group’s target price suggests a potential upside of 18.51% from the company’s previous close.

A number of other equities research analysts have also issued reports on the stock. Wells Fargo & Company increased their target price on shares of Eastman Chemical from $114.00 to $120.00 and gave the stock an “overweight” rating in a report on Tuesday, February 2nd. Zacks Investment Research lowered shares of Eastman Chemical from a “buy” rating to a “hold” rating and set a $105.00 target price on the stock. in a report on Thursday, January 28th. Tudor Pickering lowered shares of Eastman Chemical from a “buy” rating to a “hold” rating and set a $117.00 target price on the stock. in a report on Monday, May 3rd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Eastman Chemical from $115.00 to $126.00 and gave the stock a “buy” rating in a report on Monday, March 22nd. Finally, KeyCorp increased their target price on shares of Eastman Chemical from $126.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $109.23. Read more …

 

 

Ventas (NYSE:VTR) was upgraded by equities researchers at Robert W. Baird from a "neutral" rating to an "outperform" rating in a note issued to investors on Thursday, The Fly reports.

A number of other equities research analysts have also weighed in on the company. KeyCorp raised Ventas from an "underweight" rating to an "overweight" rating and lifted their price objective for the company from $49.00 to $60.00 in a report on Thursday. Morgan Stanley upped their price objective on Ventas from $52.00 to $58.00 and gave the stock an "equal weight" rating in a report on Monday, March 22nd. Zacks Investment Research upgraded Ventas from a "strong sell" rating to a "hold" rating and set a $58.00 price objective for the company in a research report on Thursday, April 8th. Mizuho boosted their target price on shares of Ventas from $38.00 to $45.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 9th. Finally, Royal Bank of Canada increased their price target on shares of Ventas from $54.00 to $58.00 and gave the company an "outperform" rating in a report on Tuesday, March 2nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of "Hold" and a consensus price target of $48.47. Read more …

Is Cardinal Health Stock A Buy?

 

Cardinal Health Inc (NYSE:CAH) built a massive footprint through a series of mergers and acquisitions. It now sells medical products to nearly all U.S. hospitals. Despite its impressive growth, the company’s share price struggled to breakthrough, either before or after the pandemic hit.

 

It sold over $152.9 billion worth of products in the 2020 fiscal year, so as an investment opportunity is Cardinal Health stock a Buy?

 

What started as a food distribution business shifted to medical equipment and pharmaceuticals over the years. When the pandemic spread, management shifted priorities to invest in connected care and specialty business segments.

 

Healthcare isn’t a cheap business – everything the company sells must be approved by the Food and Drug Administration (FDA). Still, it manages to be one of the highest revenue-generating companies in the United States.

 

Can Cardinal Health continue generating those healthy revenues?

 

Cardinal Health Is A Drug & Device Giant

Cardinal Health started as Cardinal Foods in 1971. It was a food wholesaler that earned enough on its bottom line to buy Baily Drug Company, and thereafter expanded into drug distribution. That led to its 1983 public offering and a long history of mergers and acquisitions.

 

 

After selling off its food business, this vertically integrated company expanded horizontally. It bought over a dozen companies to expand its drug and device manufacturing and distribution capabilities.

 

Today, it offers logistics, products, technology, and business services to nearly 90 percent of all U.S. hospitals. It also provides products to labs, pharmacies, specialty offices and clinics, and home healthcare.

 

Continue reading …

 

Notable Analyst Upgrades and Downgrades for Week of November 2, 2020

 

Upgrades:

 

Cardinal Health (NYSE:CAH) was upgraded by investment analysts at Barclays from an “equal weight” rating to an “overweight” rating in a note issued to investors on Monday, Anlyst Ratings reports. The brokerage presently has a $57.00 price target on the stock. Barclays‘s price objective suggests a potential upside of 24.48% from the company’s current price.

Other research analysts have also issued reports about the company. Morgan Stanley upped their price objective on Cardinal Health from $59.00 to $61.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. UBS Group reduced their target price on Cardinal Health from $65.00 to $64.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Bank of America increased their target price on Cardinal Health from $61.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Guggenheim raised Cardinal Health from a “neutral” rating to a “buy” rating in a report on Monday, July 20th. Finally, Zacks Investment Research raised Cardinal Health from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a report on Thursday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $58.90. Read more …

 

McKesson (NYSE:MCK) was upgraded by stock analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research report issued on Monday, AnalystRatings.net reports. The firm currently has a $166.00 price objective on the stock. Barclays‘s price objective would indicate a potential upside of 12.55% from the stock’s previous close.

Several other equities research analysts have also commented on the stock. ValuEngine upgraded shares of McKesson from a “strong sell” rating to a “sell” rating in a research note on Monday, October 19th. Zacks Investment Research downgraded shares of McKesson from a “hold” rating to a “sell” rating and set a $161.00 price objective on the stock. in a research report on Thursday, July 16th. Credit Suisse Group raised their price objective on shares of McKesson from $160.00 to $162.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. raised their price objective on shares of McKesson from $187.00 to $198.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, Guggenheim raised their price objective on shares of McKesson from $168.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $178.00. Read more …

 

GlaxoSmithKline (NYSE:GSK) was upgraded by Liberum Capital from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, The Fly reports.

Several other brokerages also recently issued reports on GSK. Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline in a research report on Friday, September 18th. Berenberg Bank began coverage on GlaxoSmithKline in a research note on Tuesday, September 29th. They issued a “buy” rating for the company. AlphaValue raised shares of GlaxoSmithKline to a “buy” rating in a report on Tuesday, September 1st. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 21st. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of GlaxoSmithKline in a research note on Friday, October 9th. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $41.00. Read more …

 

 

 

Intel (NASDAQ:INTC) was upgraded by stock analysts at The Goldman Sachs Group from a “sell” rating to a “neutral” rating in a research note issued to investors on Wednesday, The Fly reports. The firm presently has a $38.00 target price on the chip maker’s stock, down from their prior target price of $46.00. The Goldman Sachs Group’s price target would indicate a potential downside of 16.04% from the company’s previous close.

Several other equities analysts also recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Intel in a research report on Tuesday, July 7th. Bank of America downgraded shares of Intel from a “neutral” rating to an “underperform” rating and lowered their target price for the stock from $60.00 to $45.00 in a research report on Friday, October 23rd. SVB Leerink initiated coverage on shares of Intel in a research report on Friday, July 24th. They set a “hold” rating on the stock. Northland Securities raised shares of Intel from an “under perform” rating to a “market perform” rating and set a $46.00 target price on the stock in a research report on Monday. Finally, Roth Capital lowered their target price on shares of Intel from $55.00 to $50.00 and set a “neutral” rating on the stock in a research report on Friday, October 23rd. Eleven analysts have rated the stock with a sell rating, eighteen have issued a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $57.69. Read more …